Skip to main content

Table 4 Change in neurodevelopment test score according to time of mPBMC infusion

From: Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study

  M0–M13 M1–M13
T1 T7 p T1 T7 p
GMFM 4.28 8.30 0.002 2.90 6.37 0.001
 Lying 1.34 1.33 0.398 0.89 0.71 0.780
 Sitting 2.65 9.08 0.103 1.74 7.35 0.044
 Crawling 5.19 12.86 0.010 2.92 10.41 0.002
 Standing 4.78 7.18 0.093 3.50 5.13 0.079
 Walking 7.45 10.02 0.391 5.43 8.45 0.198
PEDI_selfcare 8.64 8.13 0.370 5.58 6.54 0.204
 Mobility 8.86 10.00 0.856 6.35 6.53 0.621
 Social function 13.78 9.33 0.327 9.54 6.28 0.296
 Selfcare (caregiver) 7.88 10.92 0.228 5.54 8.44 0.455
 Mobility (caregiver) 4.90 7.28 0.221 3.29 6.22 0.052
 Social function (caregiver) 11.45 14.65 0.236 8.87 12.13 0.208
QUEST 21.28 25.66 0.394 13.79 18.44 0.183
  1. mPBMC mobilized peripheral blood mononuclear cell; GMFM gross motor function measure; PEDI pediatric evaluation of disability inventory; QUEST quality of upper extremity skills test. M0, M1, and M13 refer to months after enrollment. T1 and T7 refer to a group who received mPBMC at 1 and 7 months of study, respectively
\